Ascendis Drug Patent Portfolio
Ascendis owns 1 orange book drug protected by 12 US patents Given below is the list of Ascendis's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12377133 | Dry Pharmaceutical Formulations Of Cnp Conjugates | 12 Nov, 2042 | Active |
| US10835578 | Cnp Prodrugs With Large Carrier Moieties | 05 Jan, 2037 | Active |
| US11154593 | Cnp Prodrugs With Large Carrier Moieties | 05 Jan, 2037 | Active |
| US11224661 | Controlled-Release Cnp Agonists With Increased Nep Stability | 05 Jan, 2037 | Active |
| US11311604 | Controlled-Release Cnp Agonists With Low Npr-C Binding | 05 Jan, 2037 | Active |
| US11389510 | Controlled-Release Cnp Agonists With Low Initial Npr-B Activity | 05 Jan, 2037 | Active |
| US11389511 | Controlled-Release Cnp Agonists With Reduced Side-Effects | 05 Jan, 2037 | Active |
| US11413351 | Cnp Prodrugs With Carrier Attachment At The Ring Moiety | 05 Jan, 2037 | Active |
| US12083182 | Controlled-Release Cnp Agonists With Increased Nep Stability | 05 Jan, 2037 | Active |
| US12156917 | Cnp Prodrugs With Carrier Attachment At The Ring Moiety | 05 Jan, 2037 | Active |
| US12239689 | Controlled-Release Cnp Agonists With Low Initial Npr-B Activity | 05 Jan, 2037 | Active |
| US8906847 | Prodrug comprising a drug linker conjugate | 30 Apr, 2031 | Active |
Ascendis's Family Patents
Ascendis Drug List
Given below is the complete list of Ascendis's drugs and the patents protecting them.
1. Yuviwel
Yuviwel is protected by 12 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12377133 | Dry Pharmaceutical Formulations Of Cnp Conjugates |
12 Nov, 2042
(16 years from now)
| Active |
| US10835578 | Cnp Prodrugs With Large Carrier Moieties |
05 Jan, 2037
(10 years from now)
| Active |
| US11154593 | Cnp Prodrugs With Large Carrier Moieties |
05 Jan, 2037
(10 years from now)
| Active |
| US11224661 | Controlled-Release Cnp Agonists With Increased Nep Stability |
05 Jan, 2037
(10 years from now)
| Active |
| US11311604 | Controlled-Release Cnp Agonists With Low Npr-C Binding |
05 Jan, 2037
(10 years from now)
| Active |
| US11389510 | Controlled-Release Cnp Agonists With Low Initial Npr-B Activity |
05 Jan, 2037
(10 years from now)
| Active |
| US11389511 | Controlled-Release Cnp Agonists With Reduced Side-Effects |
05 Jan, 2037
(10 years from now)
| Active |
| US11413351 | Cnp Prodrugs With Carrier Attachment At The Ring Moiety |
05 Jan, 2037
(10 years from now)
| Active |
| US12083182 | Controlled-Release Cnp Agonists With Increased Nep Stability |
05 Jan, 2037
(10 years from now)
| Active |
| US12156917 | Cnp Prodrugs With Carrier Attachment At The Ring Moiety |
05 Jan, 2037
(10 years from now)
| Active |
| US12239689 | Controlled-Release Cnp Agonists With Low Initial Npr-B Activity |
05 Jan, 2037
(10 years from now)
| Active |
| US8906847 | Prodrug comprising a drug linker conjugate |
30 Apr, 2031
(5 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Yuviwel's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List